About: Tecelac as antithymocyte globulin in conditioning for childhood allogeneic stem cell transplantation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tecelac as antithymocyte globulin in conditioning for childhood allogeneic stem cell transplantation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Tecelac as antithymocyte globulin in conditioning for childhood allogeneic stem cell transplantation
Creator	Zimmermann, S Klingebiel, T Koehl, U Schwabe, D Soerensen, J
Source	PMC
abstract	Antithymocyte globulin (ATG) preparations in allogeneic stem cell transplantation are used in various conditioning regimens both to prevent graft rejection and reduce the incidence and severity of graft-versus-host disease. Tecelac (RATG) is a highly purified ATG preparation with high specific activity. The high specific antibody content implies the need for lower doses, with reduced side-effects in comparison to other ATGs. Here, we report on the first 10 patients worldwide who received RATG as part of conditioning. Patients were heterogeneous with regard to diagnoses and graft characteristics. RATG was given in cases of matched unrelated donors, mismatched family donors, reduced conditioning, or high risk for graft failure. Mostly mild allergic reactions toward RATG were seen. All of the patients engrafted in due time. Two died within 2 months of transplant of pulmonary complications not related to RATG. Two developed GVHD grade I, no chronic GVHD was seen to date. Viremia occurred in two, with no viral disease developed. Of the eight patients surviving, one suffered relapse of acute leukemia, one shows impending graft failure. The others are well. Using RATG in conditioning is feasible.
has issue date	2002-07-05(xsd:dateTime)
bibo:doi	10.1038/sj.bmt.1703561
bibo:pmid	12098062
has license	no-cc
sha1sum (hex)	2bc32d5df1c0d8656799d0cc8355be8b5aa4aa0d
schema:url	https://doi.org/10.1038/sj.bmt.1703561
resource representing a document's title	Tecelac as antithymocyte globulin in conditioning for childhood allogeneic stem cell transplantation
has PubMed Central identifier	PMC7091629
has PubMed identifier	12098062
schema:publication	Bone Marrow Transplant
resource representing a document's body	covid:2bc32d5df1c0d8656799d0cc8355be8b5aa4aa0d#body_text
is schema:about of	named entity 'acute leukemia' named entity 'graft rejection' named entity 'high risk' named entity 'graft' named entity 'incidence' named entity 'Viremia' named entity 'PURIFIED' named entity 'ALLERGIC REACTIONS' named entity 'USING' named entity 'FEASIBLE' named entity 'NEED FOR' named entity 'TO PREVENT' named entity 'DOSES' covid:arg/2bc32d5df1c0d8656799d0cc8355be8b5aa4aa0d named entity 'specific activity' named entity 'allogeneic stem cell transplantation' named entity 'chronic' named entity 'antibody' named entity 'graft' named entity 'prevent' named entity 'donors' named entity 'ATG' named entity 'GVHD' named entity 'viral disease' named entity 'Two' named entity 'antithymocyte globulin' named entity 'viral disease' named entity 'side-effects' named entity 'pulmonary complications' named entity 'relapse' named entity 'conditioning regimens' named entity 'allogeneic stem cell transplantation' named entity 'Conditioning regimens' named entity 'conditioning' named entity 'bone marrow' named entity 'diarrhea' named entity 'lymphocytes' named entity 'GVHD' named entity 'infusion' named entity 'GVHD' named entity 'ARDS' named entity 'allogeneic stem cell transplantation' named entity 'cidofovir' named entity 'infusion' named entity 'blood pressure' named entity 'PBSC' named entity 'conditioning regimens' named entity 'G-CSF' named entity 'lymphocytes' named entity 'chronic phase' named entity 'cyclophosphamide' named entity 'toxicity' named entity 'graft-versus-host' named entity 'ATG' named entity 'peripheral blood stem cells' named entity 'hyperimmunization' named entity 'refractory' named entity 'clinical signs' named entity 'thymocytes' named entity 'dyspnea' named entity 'microbial' named entity 'neutrophils' named entity 'platelets' named entity 'Cyclophosphamide' named entity 'PCR' named entity 'antibodies' named entity 'polyclonal' named entity 'fludarabine' named entity 'fever' named entity 'administered intravenously' named entity 'virus' named entity 'immunosuppression' named entity 'antibodies' named entity 'respiratory failure' named entity 'prophylaxis' named entity 'Chimerism' named entity 'CML'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software